Literature DB >> 8576093

Temporally distinctive changes of alternative splicing patterns during myogenic differentiation of C2C12 cells.

Y Harada1, M Nakamura, A Asano.   

Abstract

It is well known that skeletal muscle differentiation is accompanied by the appearance of many muscle-specific components and that some of these components are generated through muscle-specific alternative splicing. It is not clear, however, in what manner, including timing, the system that regulates the muscle-specific splicing reactions is constructed during the process of myogenic differentiation. We simultaneously examined the changes in several splicing patterns for the neural cell adhesion molecule (NCAM), beta-tropomyosin, and M-type pyruvate kinase genes during myogenic differentiation of cultured myoblasts using the reverse transcription-polymerase chain reaction method. The NCAM glycosylphosphatidylinositol anchor form increased in preference to the transmembrane form immediately after the induction of differentiation, while the selection of NCAM MSD1 (muscle-specific domain 1) exons started and abruptly increased at about the time when cell-fusion appeared. M2-type pyruvate kinase was gradually substituted for the M1-type molecule. Skeletal muscle-type beta-tropomyosin was predominantly selected even in myoblasts in the growth medium. As a result, each transcript of these genes independently showed a temporally distinctive pattern of change in isoform selecting during the myogenic differentiation of C2C12 cells. These observations suggest that some independent regulation of alternative splicing reactions should occur during myogenic differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576093     DOI: 10.1093/oxfordjournals.jbchem.a124980

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  8 in total

Review 1.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.

Authors:  Mo Chen; Jian Zhang; James L Manley
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

3.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

4.  Pyruvate Kinase M2 Supports Muscle Progenitor Cell Proliferation but Is Dispensable for Skeletal Muscle Regeneration after Injury.

Authors:  Jamie E Blum; Brandon J Gheller; Abby Benvie; Martha S Field; Elena Panizza; Nathaniel M Vacanti; Daniel Berry; Anna Thalacker-Mercer
Journal:  J Nutr       Date:  2021-11-02       Impact factor: 4.687

Review 5.  A metabolic link to skeletal muscle wasting and regeneration.

Authors:  René Koopman; C Hai Ly; James G Ryall
Journal:  Front Physiol       Date:  2014-02-03       Impact factor: 4.566

6.  Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis.

Authors:  Xinlu Ren; Yi Dong; Miao Duan; Hui Zhang; Peng Gao
Journal:  Oncol Lett       Date:  2020-11-17       Impact factor: 2.967

7.  Mapping and modeling the genomic basis of differential RNA isoform expression at single-cell resolution with LR-Split-seq.

Authors:  Elisabeth Rebboah; Fairlie Reese; Katherine Williams; Gabriela Balderrama-Gutierrez; Cassandra McGill; Diane Trout; Isaryhia Rodriguez; Heidi Liang; Barbara J Wold; Ali Mortazavi
Journal:  Genome Biol       Date:  2021-10-07       Impact factor: 13.583

8.  Nuclear pyruvate kinase M2 complex serves as a transcriptional coactivator of arylhydrocarbon receptor.

Authors:  Shun Matsuda; Jun Adachi; Masaru Ihara; Nobuhiro Tanuma; Hiroshi Shima; Akira Kakizuka; Masae Ikura; Tsuyoshi Ikura; Tomonari Matsuda
Journal:  Nucleic Acids Res       Date:  2015-09-23       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.